Inicio › Trastorno depresivo mayor › Florida › Tampa
Ensayos clínicos de Trastorno depresivo mayor en Tampa, FL
17 estudios para Trastorno depresivo mayor buscan participantes en centros de Tampa y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
ReclutandoFase 2
- IPTB Clinical Research, Tampa
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
ReclutandoFase 3
- K2 Medical Research Tampa, Tampa
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
ReclutandoFase 3
- K2 Medical Research (Tampa), Tampa
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
ReclutandoFase 3
- K2 Medical Research - Tampa, Tampa
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
ReclutandoFase 3
- IPTB Clinical Research, Tampa
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
ReclutandoFase 3
- Interventional Psychiatry of Tampa Bay, Tampa
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
ReclutandoFase 3
- Psych Me Medical Research Inc, Tampa
- Interventional Psychiatry of Tampa Bay, Tampa
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
ReclutandoFase 2
- K2 Medical Research - Tampa, Tampa
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
ReclutandoFase 4
- Neurocrine Clinical Site, Tampa
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
ReclutandoFase 2
- Draig Clinical Site, Tampa
- Draig Clinical Site, Tampa
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Reclutando
- USF Health, Tampa
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
ReclutandoFase 3
- Neurocrine Clinical Site, Tampa
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
ReclutandoFase 3
- Neurocrine Clinical Site, Tampa
- Neurocrine Clinical Site, Tampa
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
ReclutandoFase 3
- Neurocrine Clinical Site, Tampa
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
ReclutandoFase 2
- University of South Florida, Psychiatry and Behavioral Neurosciences, Tampa
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
ReclutandoFase 2
- Autobahn Site #148, Tampa
Study of ALTO-300 in MDD
ReclutandoFase 2
- Site 221, Tampa
Ensayos de Trastorno depresivo mayor en otras ciudades
- New York City, NY36 estudios
- Boston, MA31 estudios
- Atlanta, GA25 estudios
- Philadelphia, PA23 estudios
- Orlando, FL19 estudios
- Miami, FL18 estudios
- Chicago, IL17 estudios
- San Diego, CA16 estudios
- Houston, TX16 estudios
- Little Rock, AR14 estudios
- Austin, TX13 estudios
- Las Vegas, NV13 estudios
Otros estudios en Tampa
- Cáncer de pulmón de células no pequeñas51 estudios
- Cáncer de seno43 estudios
- Cáncer (todos los tipos)39 estudios
- Cáncer del colon y del recto34 estudios
- Leucemia mielógena aguda29 estudios
- Cáncer metastásico29 estudios
- Cáncer de pulmón29 estudios
- Cáncer de páncreas26 estudios
- Cáncer de ovario21 estudios
- Melanoma19 estudios
- Síndromes mielodisplásicos19 estudios
- Cáncer de próstata18 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.